Ultragenyx Pharmaceutical(RARE) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For 2025, the company reported total revenue of $673 million, representing a 20% growth over 2024, exceeding the upper end of guidance [10] - The net loss for the year was $575 million, or $5.83 per share, with cash, cash equivalents, and marketable securities totaling $738 million as of December 31 [11] Business Line Data and Key Metrics Changes - Crysvita contributed $481 million, with a 17% growth over 2024, exceeding guidance [10] - Dojolvi generated $96 million, reflecting a 9% growth over 2024 [10] - Evkeeza saw significant growth, contributing $59 million, representing an 84% increase over 2024 [10] - Mepsevii contributed $37 million, continuing to treat patients in an ultra-rare indication [10] Market Data and Key Metrics Changes - The commercial business delivered a significant 20% year-over-year growth in 2025, with treatments reaching over 35 countries [6] - The company anticipates total revenue in 2026 to be between $730 million and $760 million, representing an 8%-13% growth over 2025 [11][12] Company Strategy and Development Direction - The company is focused on achieving profitability by 2027 through a strategic restructuring plan that includes a 10% workforce reduction and realignment of resources towards high-impact opportunities [7][9] - The company aims to launch three additional treatments over the next two years while continuing to grow its existing commercial products [9][22] Management's Comments on Operating Environment and Future Outlook - Management highlighted 2026 as a significant year with potential approvals in key programs and pivotal data readouts [3] - The company is addressing the FDA's incomplete response letter regarding UX111 and is working to provide additional documentation for resubmission [5][20] - Management expressed confidence in the ability to deliver the next phase of growth required to reach profitability [19] Other Important Information - The company is implementing a strategic restructuring plan to reduce operating expenses while advancing its product pipeline [7][9] - The company expects combined R&D and SG&A expenses to be flat to down low single digits in 2026 compared to 2025 [12] Q&A Session Summary Question: Regarding the primary endpoint for the phase 3 Angelman study - The decision to use cognition over expressive communication was based on its fundamental importance and the complexities of communication development [24][25] Question: Can you provide insights on the patient baseline profile for the phase 3 study? - The baseline data from the phase 3 program is comparable to the expansion trial, providing confidence in the study's design [29][30] Question: How does the company plan to achieve profitability in 2027? - The pathway to profitability includes continued growth from current products and cost reductions, with expectations for combined R&D and SG&A expenses to decrease significantly by 2027 [35][36] Question: Can you clarify the timeline for the IRL resubmission? - The resubmission timeline is similar to the original submission, with a PDUFA date expected approximately six months after resubmission [68][69] Question: What is the expected launch trajectory for DTX-401? - The launch is expected to develop steadily, with strong demand anticipated, but not an immediate steep uptake [72]